VP3-2022: Pembrolizumab (pembro) versus placebo for early-stage non-small cell lung cancer (NSCLC) following complete resection and adjuvant chemotherapy (chemo) when indicated: Randomized, triple-blind, phase III EORTC-1416-LCG/ETOP 8-15 – PEARLS/KEYNOTE-091 study

L. Paz-Ares, E O’Brien, M. Mauer, Urania Dafni, Kersti Oselin, Libor Havel, E. Esteban Gonzalez, Dolores Isla, Alex Martínez‐Martí, Martin Faehling, Masahiro Tsuboi, JS Lee, Kouichi Nakagawa, Jiong Yang, S.M. Keller, Nitish Jha, Sandrine Marréaud, R.A. Stahel, Solange Peters, Benjamin Besse